0001209191-20-025022.txt : 20200417 0001209191-20-025022.hdr.sgml : 20200417 20200417210906 ACCESSION NUMBER: 0001209191-20-025022 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200415 FILED AS OF DATE: 20200417 DATE AS OF CHANGE: 20200417 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Pande Atul CENTRAL INDEX KEY: 0001643071 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37418 FILM NUMBER: 20801103 MAIL ADDRESS: STREET 1: C/O AXOVANT SCIENCES, INC. STREET 2: 1441 BROADWAY, 3RD FLOOR CITY: NEW YORK STATE: NY ZIP: 10018 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Axovant Gene Therapies Ltd. CENTRAL INDEX KEY: 0001636050 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 981333697 FISCAL YEAR END: 0331 BUSINESS ADDRESS: STREET 1: 11-12 ST. JAMES'S SQUARE STREET 2: SUITE 1, 3RD FLOOR CITY: LONDON STATE: X0 ZIP: SW1Y 4LB BUSINESS PHONE: 44 203 318 9708 MAIL ADDRESS: STREET 1: 11 TIMES SQUARE STREET 2: 33RD FLOOR CITY: NEW YORK STATE: NY ZIP: 10036 FORMER COMPANY: FORMER CONFORMED NAME: Axovant Sciences Ltd. DATE OF NAME CHANGE: 20150324 FORMER COMPANY: FORMER CONFORMED NAME: Axovant Sciences, Inc. DATE OF NAME CHANGE: 20150324 FORMER COMPANY: FORMER CONFORMED NAME: Roivant Neurosciences Ltd. DATE OF NAME CHANGE: 20150309 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2020-04-15 0 0001636050 Axovant Gene Therapies Ltd. AXGT 0001643071 Pande Atul C/O AXOVANT GENE THERAPIES LTD. 11 TIMES SQUARE, 33RD FLOOR NEW YORK NY 10036 1 0 0 0 Stock Option (Right to Buy) 3.45 2020-04-15 4 A 0 17500 0.00 A 2030-04-14 Common Shares 17500 17500 D 100% of this option will vest on April 15, 2021, subject to the Reporting Person providing continuous service to the Issuer on such date. The option allows for early exercise, subject to the Issuer's repurchase option with respect to any unvested common shares. All common shares underlying the option will become fully vested upon a change in control, as that term is defined in the Issuer's 2015 Equity Incentive Plan. /s/ Alison Haggerty, Attorney-In-Fact 2020-04-17